Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| HTS_SELF |
|
2019 |
2,475 |
| HTS_SELF |
15-19, Female, Directly-Assisted |
2019 |
22 |
| HTS_SELF |
15-19, Female, Unassisted |
2019 |
37 |
| HTS_SELF |
15-19, Male, Directly-Assisted |
2019 |
59 |
| HTS_SELF |
15-19, Male, Unassisted |
2019 |
117 |
| HTS_SELF |
20-24, Female, Directly-Assisted |
2019 |
72 |
| HTS_SELF |
20-24, Female, Unassisted |
2019 |
138 |
| HTS_SELF |
20-24, Male, Directly-Assisted |
2019 |
211 |
| HTS_SELF |
20-24, Male, Unassisted |
2019 |
408 |
| HTS_SELF |
25-29, Female, Directly-Assisted |
2019 |
73 |
| HTS_SELF |
25-29, Female, Unassisted |
2019 |
139 |
| HTS_SELF |
25-29, Male, Directly-Assisted |
2019 |
219 |
| HTS_SELF |
25-29, Male, Unassisted |
2019 |
430 |
| HTS_SELF |
30-34, Female, Directly-Assisted |
2019 |
37 |
| HTS_SELF |
30-34, Female, Unassisted |
2019 |
80 |
| HTS_SELF |
30-34, Male, Directly-Assisted |
2019 |
117 |
| HTS_SELF |
30-34, Male, Unassisted |
2019 |
233 |
| HTS_SELF |
35-39, Male, Directly-Assisted |
2019 |
8 |
| HTS_SELF |
35-39, Male, Unassisted |
2019 |
14 |
| HTS_SELF |
40-49, Male, Directly-Assisted |
2019 |
8 |
| HTS_SELF |
40-49, Male, Unassisted |
2019 |
14 |
| HTS_SELF |
50+, Male, Directly-Assisted |
2019 |
8 |
| HTS_SELF |
50+, Male, Unassisted |
2019 |
31 |
| HTS_SELF |
Directly-Assisted |
2019 |
834 |
| HTS_SELF |
Unassisted |
2019 |
1,641 |
| HTS_TST |
25-29, Female, Negative |
2019 |
318 |
| HTS_TST |
25-29, Female, Negative |
2019 |
93 |
| HTS_TST |
25-29, Female, Negative |
2019 |
788 |
| HTS_TST |
25-29, Male, Negative |
2019 |
758 |
| HTS_TST |
25-29, Male, Negative |
2019 |
222 |
| HTS_TST |
25-29, Male, Negative |
2019 |
1,863 |
| HTS_TST |
30-34, Female, Negative |
2019 |
283 |
| HTS_TST |
30-34, Female, Negative |
2019 |
81 |
| HTS_TST |
30-34, Female, Negative |
2019 |
685 |
| HTS_TST |
30-34, Male, Negative |
2019 |
715 |
| HTS_TST |
30-34, Male, Negative |
2019 |
210 |
| HTS_TST |
30-34, Male, Negative |
2019 |
1,767 |
| HTS_TST |
35-39, Female, Negative |
2019 |
157 |
| HTS_TST |
35-39, Female, Negative |
2019 |
47 |
| HTS_TST |
35-39, Female, Negative |
2019 |
391 |
| HTS_TST |
35-39, Male, Negative |
2019 |
318 |
| HTS_TST |
35-39, Male, Negative |
2019 |
93 |
| HTS_TST |
35-39, Male, Negative |
2019 |
788 |
| HTS_TST |
40-49, Female, Negative |
2019 |
79 |
| HTS_TST |
40-49, Female, Negative |
2019 |
24 |
| HTS_TST |
40-49, Female, Negative |
2019 |
198 |
| HTS_TST |
40-49, Male, Negative |
2019 |
198 |
| HTS_TST |
40-49, Male, Negative |
2019 |
79 |
| HTS_TST |
40-49, Male, Negative |
2019 |
24 |
| HTS_TST |
By Key Population: FSW, Negative |
2019 |
871 |
| HTS_TST |
By Key Population: MSM, Negative |
2019 |
2,072 |
| HTS_TST |
By Key Population: People in prisons and other enclosed settings, Negative |
2019 |
113 |
| HTS_TST |
By Key Population: PWID, Negative |
2019 |
2,979 |
| HTS_TST |
By Key Population: TG, Negative |
2019 |
26 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2019 |
16,141 |
| HTS_TST |
Service Delivery Point (Facility) Index: 15-19, Female, Negative |
2019 |
79 |
| HTS_TST |
Service Delivery Point (Facility) Index: 15-19, Male, Negative |
2019 |
121 |
| HTS_TST |
Service Delivery Point (Facility) Index: 20-24, Female, Negative |
2019 |
240 |
| HTS_TST |
Service Delivery Point (Facility) Index: 20-24, Male, Negative |
2019 |
758 |
| HTS_TST |
Service Delivery Point (Facility) Index: 50+, Female, Negative |
2019 |
42 |
| HTS_TST |
Service Delivery Point (Facility) Index: 50+, Male, Negative |
2019 |
37 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative |
2019 |
24 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative |
2019 |
36 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative |
2019 |
69 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative |
2019 |
222 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative |
2019 |
12 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative |
2019 |
8 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 15-19, Female, Negative |
2019 |
198 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 15-19, Male, Negative |
2019 |
294 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 20-24, Female, Negative |
2019 |
589 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 20-24, Male, Negative |
2019 |
1,863 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 50+, Female, Negative |
2019 |
96 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 50+, Male, Negative |
2019 |
101 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
25 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
6 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
60 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
68 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
17 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
141 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
22 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
6 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
51 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
59 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
15 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
133 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
14 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
26 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
25 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
5 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
60 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
8 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
14 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
14 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
8 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
3 |
| HTS_TST_POS |
By Key Population: FSW, Positive |
2019 |
14 |
| HTS_TST_POS |
By Key Population: MSM, Positive |
2019 |
190 |
| HTS_TST_POS |
By Key Population: PWID, Positive |
2019 |
112 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 15-19, Female, Positive |
2019 |
8 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 15-19, Male, Positive |
2019 |
13 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 20-24, Female, Positive |
2019 |
22 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 20-24, Male, Positive |
2019 |
68 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 50+, Male, Positive |
2019 |
6 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive |
2019 |
3 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive |
2019 |
6 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive |
2019 |
18 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 15-19, Female, Positive |
2019 |
14 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 15-19, Male, Positive |
2019 |
22 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 20-24, Female, Positive |
2019 |
45 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 20-24, Male, Positive |
2019 |
141 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 50+, Female, Positive |
2019 |
8 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 50+, Male, Positive |
2019 |
10 |
| KP_PREV |
By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
1,734 |
| KP_PREV |
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
521 |
| KP_PREV |
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
5,375 |
| KP_PREV |
By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
4,330 |
| KP_PREV |
By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
172 |
| KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2019 |
12,132 |
| PP_PREV |
25-29, Female |
2019 |
286 |
| PP_PREV |
25-29, Male |
2019 |
859 |
| PP_PREV |
30-34, Female |
2019 |
286 |
| PP_PREV |
30-34, Male |
2019 |
859 |
| PP_PREV |
35-39, Female |
2019 |
200 |
| PP_PREV |
35-39, Male |
2019 |
586 |
| PP_PREV |
40-49, Female |
2019 |
200 |
| PP_PREV |
40-49, Male |
2019 |
586 |
| PP_PREV |
Age/sex: 10-14 Female |
2019 |
39 |
| PP_PREV |
Age/sex: 10-14 Male |
2019 |
114 |
| PP_PREV |
Age/sex: 15-19 Female |
2019 |
39 |
| PP_PREV |
Age/sex: 15-19 Male |
2019 |
114 |
| PP_PREV |
Age/sex: 20-24 Female |
2019 |
200 |
| PP_PREV |
Age/sex: 20-24 Male |
2019 |
586 |
| PP_PREV |
Age/sex: 50+ Female |
2019 |
66 |
| PP_PREV |
Age/sex: 50+ Male |
2019 |
180 |
| PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2019 |
5,200 |
| PP_PREV |
Sum of Age/Sex disaggregates |
2019 |
1,338 |
| PrEP_NEW |
25-29, Female |
2019 |
133 |
| PrEP_NEW |
25-29, Male |
2019 |
396 |
| PrEP_NEW |
30-34, Female |
2019 |
61 |
| PrEP_NEW |
30-34, Male |
2019 |
179 |
| PrEP_NEW |
35-39, Female |
2019 |
23 |
| PrEP_NEW |
35-39, Male |
2019 |
65 |
| PrEP_NEW |
40-49, Female |
2019 |
11 |
| PrEP_NEW |
40-49, Male |
2019 |
30 |
| PrEP_NEW |
Female 15-19 |
2019 |
11 |
| PrEP_NEW |
Female 20-24 |
2019 |
133 |
| PrEP_NEW |
Female 50+ |
2019 |
11 |
| PrEP_NEW |
Male 15-19 |
2019 |
35 |
| PrEP_NEW |
Male 20-24 |
2019 |
396 |
| PrEP_NEW |
Male 50+ |
2019 |
16 |
| PrEP_NEW |
MSM |
2019 |
1,350 |
| PrEP_NEW |
Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection |
2019 |
1,500 |
| PrEP_NEW |
Other Key Populations |
2019 |
74 |
| PrEP_NEW |
TG |
2019 |
76 |
| TB_PREV |
By Age/Sex (Numerator): <15, Female |
2019 |
13 |
| TB_PREV |
By Age/Sex (Numerator): <15, Male |
2019 |
13 |
| TB_PREV |
By Age/Sex (Numerator): 15+, Female |
2019 |
264 |
| TB_PREV |
By Age/Sex (Numerator): 15+, Male |
2019 |
486 |
| TB_PREV |
The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period |
2019 |
776 |
| TB_PREV |
The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) |
2019 |
913 |
| TB_PREV_den |
By Age/Sex (Denominator): <15, Female |
2019 |
15 |
| TB_PREV_den |
By Age/Sex (Denominator): <15, Male |
2019 |
15 |
| TB_PREV_den |
By Age/Sex (Denominator): 15+, Female |
2019 |
308 |
| TB_PREV_den |
By Age/Sex (Denominator): 15+, Male |
2019 |
575 |
| TX_CURR |
25-29, Female, Positive |
2019 |
1,413 |
| TX_CURR |
25-29, Male, Positive |
2019 |
2,670 |
| TX_CURR |
30-34, Female, Positive |
2019 |
1,258 |
| TX_CURR |
30-34, Male, Positive |
2019 |
2,517 |
| TX_CURR |
35-39, Female, Positive |
2019 |
627 |
| TX_CURR |
35-39, Male, Positive |
2019 |
1,258 |
| TX_CURR |
40-49, Female, Positive |
2019 |
313 |
| TX_CURR |
40-49, Male, Positive |
2019 |
313 |
| TX_CURR |
Age/Sex: <1-9 |
2019 |
411 |
| TX_CURR |
Age/Sex: 10-14 Female |
2019 |
206 |
| TX_CURR |
Age/Sex: 10-14 Male |
2019 |
205 |
| TX_CURR |
Age/Sex: 15-19 Female |
2019 |
313 |
| TX_CURR |
Age/Sex: 15-19 Male |
2019 |
472 |
| TX_CURR |
Age/Sex: 20-24 Female |
2019 |
1,413 |
| TX_CURR |
Age/Sex: 20-24 Male |
2019 |
2,829 |
| TX_CURR |
Age/Sex: 50+ Female |
2019 |
159 |
| TX_CURR |
Age/Sex: 50+ Male |
2019 |
158 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
16,535 |
| TX_CURR |
Sum of age/sex disaggregates |
2019 |
785 |
| TX_NEW |
25-29, Female, Positive |
2019 |
147 |
| TX_NEW |
25-29, Male, Positive |
2019 |
277 |
| TX_NEW |
30-34, Female, Positive |
2019 |
131 |
| TX_NEW |
30-34, Male, Positive |
2019 |
260 |
| TX_NEW |
35-39, Female, Positive |
2019 |
65 |
| TX_NEW |
35-39, Male, Positive |
2019 |
130 |
| TX_NEW |
40-49, Female, Positive |
2019 |
33 |
| TX_NEW |
40-49, Male, Positive |
2019 |
33 |
| TX_NEW |
By Age/Sex: 1-9 |
2019 |
21 |
| TX_NEW |
By Age/Sex: 10-14 Female |
2019 |
11 |
| TX_NEW |
By Age/Sex: 10-14 Male |
2019 |
9 |
| TX_NEW |
By Age/Sex: 15-19 Female |
2019 |
33 |
| TX_NEW |
By Age/Sex: 15-19 Male |
2019 |
48 |
| TX_NEW |
By Age/Sex: 20-24 Female |
2019 |
146 |
| TX_NEW |
By Age/Sex: 20-24 Male |
2019 |
293 |
| TX_NEW |
By Age/Sex: 50+ Female |
2019 |
16 |
| TX_NEW |
By Age/Sex: 50+ Male |
2019 |
18 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
1,671 |
| TX_NEW |
Sum of Age/Sex disaggregates |
2019 |
574 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2019 |
16,567 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Female Routine |
2019 |
257 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Male Routine |
2019 |
257 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2019 |
5,618 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2019 |
10,435 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2019 |
16,567 |
| TX_RET |
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
23 |
| TX_RET |
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
341 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
21 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
642 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2019 |
1,027 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2019 |
1,141 |
| TX_RET_den |
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
25 |
| TX_RET_den |
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
385 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
23 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
708 |
| TX_TB |
Number of ART patients who were screened for TB at least once during the reporting period |
2019 |
14,883 |
| TX_TB |
Number of ART patients who were started on TB treatment during the reporting period |
2019 |
248 |
| TX_TB |
Numerator: By Aggregated Age/Sex: 15+, Female |
2019 |
82 |
| TX_TB |
Numerator: By Aggregated Age/Sex: 15+, Male |
2019 |
166 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex: <15, Female |
2019 |
230 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex: <15, Male |
2019 |
230 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex:15+, Female |
2019 |
5,046 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex:15+, Male |
2019 |
9,377 |
